<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512628</url>
  </required_header>
  <id_info>
    <org_study_id>B1111-140-010</org_study_id>
    <nct_id>NCT01512628</nct_id>
  </id_info>
  <brief_title>Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty</brief_title>
  <official_title>Hemostatic Changes After Colloid Fluid Administration During Total Hip Replacement Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators administered different kinds of colloids before transfusion of red blood
      cell to patient undergoing total hip replacement arthroplasty. The investigators will compare
      the differences of changes in rotational thromboelastometry (ROTEM) data among them.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INTEM parameters change from preoperative values at post-operation</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
    <description>clotting time (sec), clot firmness time (sec), alpah angle, maximum clot firmness (mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EXTEM parameters change from preoperative values at post-operation</measure>
    <time_frame>30 minutes before and 30 minutes after operation.</time_frame>
    <description>clotting time (sec), clot firmness time (sec), alpah angle, maximum clot firmness (mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FIBTEM parameters change from preoperative values at post-operation</measure>
    <time_frame>30 min before and 30 min after operation</time_frame>
    <description>maximum clot firmness (mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infused total fluid volume</measure>
    <time_frame>Participants will be followed for the duration of THRA operation in operating room, an expected average tiem of 3 hours</time_frame>
    <description>crystalloid and colloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative blood loss</measure>
    <time_frame>postoperative 1 day and 2 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Time-Internatiolnal Normalized Ratio</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thrombin Time</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrolytes</measure>
    <time_frame>30 minutes before operation and 30 minutes after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Avascular Necrosis of Hip</condition>
  <condition>Total Hip Replacement Arthroplasty</condition>
  <arm_group>
    <arm_group_label>PENTA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentaspan is administered as a colloid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>voluVEN group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voluven is administered as a colloid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>voluLYTE group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volulyte is administered as a colloid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentaspan, voluven, volulyte</intervention_name>
    <description>Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.</description>
    <arm_group_label>PENTA group</arm_group_label>
    <arm_group_label>voluVEN group</arm_group_label>
    <arm_group_label>voluLYTE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as avascular necrosis of hip and undergoing total hip replacement
             arthroplasty

        Exclusion Criteria:

          -  hematologic disease

          -  anticoagulant medication

          -  preoperative hemoglobin &lt; 10 g/dl

          -  renal disease

          -  pulmonary disease (pulmonary edema, effusion)

          -  cardiovascular disease (coronary heart disease, congestive heart failure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyounggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 26, 2014</last_update_submitted>
  <last_update_submitted_qc>January 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

